WITHDRAWN Budget Impact of Maintenance and Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Moderate Asthma in Costa Rica
Author(s)
ABSTRACT WITHDRAWN
OBJECTIVES: Asthma is a heterogeneous disease characterized by airways inflammation. Daily inhaled corticosteroid (ICS) with a long-acting beta-agonist (LABA) plus short-acting beta-agonist (SABA) as reliever is the standard of care (SoC) in Costa Rica for moderate asthma. Single inhaler combination budesonide–formoterol (Bud-Form) as both maintenance and reliever therapy (SMART) is more effective than ICS-LABA combination plus SABA as reliever in reducing oral corticosteroids use, emergency room (ER) visits and hospitalizations; however, in Costa Rica the information on the budget impact about efficacy of SMART in patients with moderate asthma is unknow.
METHODS: A model comparing Bud-Form SMART vs. daily ICS+LABA (separate devices) plus SABA as reliever therapy (SoC) was performed. Data was based on treatment-related outcomes from published clinical trials and drugs, ER visits, and hospitalizations from an advisory board with local pulmonologists. A market share for SMART of 2% first year, 10% second year, and 15% third year; was assumed. The currency was American dollars (USD). Costs per inhaler: Bud-Form 160/4,5µg, $28,37; beclomethasone 100µg, $2,37; formoterol 12µg, $22,80; and salbutamol 100µg, $1,25. Salbutamol and beclomethasone have 200 doses, Bud-Form has 120 doses, and formoterol has 60 doses. Mean number of inhalations: SMART=2.52 inhalations/day, beclomethasone=6 inhalations/day; formoterol=2 inhalations/day; and salbutamol=2.53 inhalations/day. Adherence of 100% for all treatments was assumed. A population of 83.849 patients in the first year; 88.776 second year; and 94.100 third year was assumed. Relapsing average costs are $645 for an ER visit and $1.244 for a hospitalization.
RESULTS: Bud-Form SMART saves $13.721 first year (-0,02%), $72.948 second year (-0,10%) and $115.985 third year (-0,16%). The savings are directly proportional to the market share of patients using SMART.
CONCLUSIONS: In Costa Rica, the total budget impact over three years due to the introduction of Bud-Form was $202.653 less expensive than SoC in patients with moderate asthma.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE679
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Thresholds & Opportunity Cost, Work & Home Productivity - Indirect Costs
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)